Core Insights - The company, Renfu Pharmaceutical, plans to raise between 3 billion to 3.5 billion yuan through a private placement to its controlling shareholder, Zhaoshang Biotechnology, which will fully subscribe in cash [1][3][4] - The funds will be allocated to five core areas, with over 1.68 billion yuan specifically earmarked for innovative drug research and development, accounting for nearly half of the total [1][3] - The company is focusing on high-barrier R&D projects in areas such as new central nervous system drugs, non-opioid analgesics, and long-acting anesthesia, with 18 projects targeting unmet clinical needs in depression, schizophrenia, and acute and chronic pain [1][4] Investment and Strategic Focus - The funding will also support the construction of a manufacturing base for sexual health and complex formulations, addressing capacity bottlenecks and facilitating rapid industrialization of innovative results [4] - The company aims to enhance its digital infrastructure to improve R&D and operational efficiency, while also supplementing working capital to optimize its financial structure for long-term innovation [4] - Renfu Pharmaceutical has established a comprehensive new drug layout across central nervous system, autoimmune, oncology, respiratory, and sexual health sectors, leveraging a multi-center R&D system and industry-academia collaboration platforms [2][4] Market Position and Future Outlook - The recent capital increase is seen as a strong endorsement of the company's strategy and innovation capabilities by the China Merchants Group, marking a significant leap in its transformation towards innovation [2][4] - The company is accelerating the transition of innovative drugs from pipeline to product and from clinical trials to market, aiming to build a more competitive pharmaceutical enterprise [2][4]